Zhou Ying, Sheng Xiao-yan, Xu Jun-yu, Bi Shan-shan, Lu Wei, Cui Yi-min
Department of Pharmacy, Base for Clinical Trial, Peking University First Hospital, Beijing 100034, China.
Int J Clin Pharmacol Ther. 2013 Jul;51(7):568-75. doi: 10.5414/CP201815.
The aim of this study is to investigate the population pharmacokinetics (PopPK) of cyclosporine (CsA) in the Chinese hematopoietic stem cell transplantation (HSCT) recipients for promoting the individualization of CsA administration.
A total of 887 retrospective drug monitoring data points were collected from 58 HSCT recipients. Whole blood samples were collected at predose (C0) and 2 hours (C2) post dose. The administration of CsA was intermittent intravenous infusion, continuous intravenous infusion and oral. Population modeling was performed using the NONMEM (nonlinear mixedeffect modeling) program. A one compartment pharmacokinetic model was used to fit the data.
Body surface area (BSA), administration route and postoperative days were identified as significant covariates for clearance (CL) according to the final model: CL = 31.0 × (BSA/1.59)0.761 × (ROUT) × (POD), where ROUT was 1.91 if the administration route was intravenous infusion, otherwise it is equal to 1. The POD was 0.818, 0.753, 0.539, and 0.509 for posttransplant Days 0 - 10, 11 - 20, 21 - 30 and more than 30 days, respectively. Administration route was a significant covariate for volume (V) according to the final model: V = 192 × (ROUT), where ROUT was 4.10, 3.63 and 1 when the administration route was continuous intravenous infusion, intermittent intravenous infusion and oral. The other covariates were not identified as a significant effect on CsA pharmacokinetic parameters.
Body surface area, administration route and postoperative days should be considered in individual pharmacotherapy of cyclosporine for HSCT patient to achieve the desired therapeutic target.
本研究旨在探讨环孢素(CsA)在中国造血干细胞移植(HSCT)受者中的群体药代动力学(PopPK),以促进CsA给药的个体化。
从58例HSCT受者中收集了总共887个回顾性药物监测数据点。在给药前(C0)和给药后2小时(C2)采集全血样本。CsA的给药方式为间歇性静脉输注、持续性静脉输注和口服。使用NONMEM(非线性混合效应建模)程序进行群体建模。采用一室药代动力学模型拟合数据。
根据最终模型,体表面积(BSA)、给药途径和术后天数被确定为清除率(CL)的显著协变量:CL = 31.0 × (BSA/1.59)0.761 × (ROUT) × (POD),其中如果给药途径为静脉输注,ROUT为1.91,否则等于1。移植后第0 - 10天、11 - 20天、21 - 30天和超过30天的POD分别为0.818、0.753、0.539和0.509。根据最终模型,给药途径是体积(V)的显著协变量:V = 192 × (ROUT),其中当给药途径为持续性静脉输注、间歇性静脉输注和口服时,ROUT分别为4.10、3.63和1。未发现其他协变量对CsA药代动力学参数有显著影响。
在对HSCT患者进行环孢素个体化药物治疗时,应考虑体表面积、给药途径和术后天数,以达到理想的治疗目标。